ZIGLIM MV 2

Distributor inventory

Type 2 diabetes mellitus in adults when diet and exercise alone or single/dual therapy is insufficient; helps control post‑meal and fasting blood glucose

Glimepiride (a sulfonylurea) increases insulin release from the pancreas. Metformin (a biguanide) reduces hepatic glucose production and improves insulin sensitivity. Voglibose (an alpha‑glucosidase inhibitor) delays carbohydrate absorption in the gut to reduce post‑meal glucose spikes.

Oral tablet. Take exactly as prescribed, usually once daily with or just after the main meal (often breakfast) to reduce stomach upset and hypoglycaemia risk. Swallow whole; do not crush/chew modified‑release tablets. Monitor blood glucose regularly.

Hypoglycaemia, nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, flatulence, bloating, headache, dizziness, weight gain

Risk of hypoglycaemia (higher with missed meals, strenuous exercise, alcohol, elderly, kidney/liver impairment); metformin may rarely cause lactic acidosis—seek urgent care for rapid breathing, severe weakness, abdominal pain, drowsiness. Use caution/avoid in severe renal impairment, severe liver disease, dehydration, severe infection, hypoxia/heart failure. Temporarily stop metformin before/after iodinated contrast and major surgery as advised. Monitor renal function, liver function, and vitamin B12 with long-term metformin.